Xceleron Expands Agreement with GlaxoSmithKline

Published: Aug 18, 2009

GERMANTOWN, Md.--(BUSINESS WIRE)--XCELERON, a leader in the field of ultra-sensitive bioanalytical studies supporting clinical research, today announced that it has signed a second Master Service Agreement with GlaxoSmithKline. Under the terms of this agreement, Xceleron will provide analytical support to GlaxoSmithKline and its affiliated research organizations. As part of the deal, Xceleron will increase capacity through the acquisition of an Accelerator Mass Spectrometry (AMS) instrument.

Back to news